Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis

Br J Dermatol. 2014 Jan;170(1):206-9. doi: 10.1111/bjd.12572.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Dermatologic Agents / adverse effects*
  • Female
  • Humans
  • Infliximab
  • Male
  • Middle Aged
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / chemically induced*
  • Psoriasis / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Dermatologic Agents
  • Infliximab